scholarly journals AB0001 INTERFERON SIGNATURE IN CHILDREN WITH CHRONIC NON-BACTERIAL OSTEOMYELITIS AND IT’S DYNAMIC AFTER BISPHOSPHONATES TREATMENT

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1036.2-1036
Author(s):  
M. Kostik ◽  
R. Raupov ◽  
R. Mulkidzhan ◽  
A. Kosmin ◽  
E. Suspitsin
Keyword(s):  
Lupus Erythematosus ◽  
Treatment Options ◽  
Basic Research ◽  
Cytokine Release ◽  
Interferon Signature ◽  
Immune Mediated ◽  
Main Adverse Event ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Basic Research Grant

Background:Chronic non-bacterial osteomyelitis (CNO) is an immune-mediated chronic inflammatory bone disease which predominantly affects children and adolescents. The pathogenesis of CNO related to imbalance between pro-inflammatory and anti-inflammatory cytokines. Interferon-I mediated pathway is associated with pathogenesis of different pediatric rheumatic diseases, such as juvenile systemic lupus erythematosus (jSLE), juvenile dermatomyositis (JDM), systemic onset of juvenile idiopathic arthritis (soJIA), and, most of all, with macrophage activation syndrome. The data on interferon-I- regulated pathway in CNO is absent. NSAIDs, non-biologic and biologic anti-inflammatory drugs and bisphosphonates (BF) are treatment options for patients with CNO. The main adverse event of BF is a flu-like syndrome probably caused by the excessive cytokine release stimulated by BF.Objectives:The aim of our study was to evaluate activity of Interferon-I mediated pathway in CNO patients and it’s dynamics after BF treatment.Methods:This prospective study included children with CNO requiring BF treatment (n=9), patients with soJIA (n=8), JDM (n=11) and jSLE (n=40) and healthy controls (HC, n=21). The activity of Interferon-I mediated pathway was assessed using interferon I score (IFN1 score). The score represented the median expression of 5 IFN1-regulated genes (IFI44L, IFI44, IFIT3, LY6E, MX1) measured by quantitative real-time PCR. Patients with CNO were treated with standard 3-day regimen (1 mg/kg/day). We measured interferon score before pamidronate (Day 0, n=9) and after (Day 3, n=7).Results:Median interferon score was 1.09 (0.96; 1.67) in CNO patients, 1.95 (1.3; 5.75) in soJIA, 7.6 (1.78; 29.0) in JDM and 16.9 (2.55; 40.3) in jSLE and 0.95 (0.82; 1.17) in HC (p=0.00001). Where were no difference in the IFN1 score between CNO and HC (p=0.222). In 6/7 CNO patients interferon score increased after pamidronate (p=0.015). The median interferon score after pamidronate increased and became 3.06 (0.87; 4,9, p=0.043); this may possibly explain the development of BF-related flu-like symptoms (cytokine release syndrome).Conclusion:While interferon I-regulated pathway is not directly associated with CNO pathogenesis, BF likely activates interferon-I-regulated pathway and thus could be a possible cause of flu-like syndrome.This work supported by the Russian Foundation for Basic Research (grant № 18-515-57001).Disclosure of Interests:None declared

scholarly journals Biomimetic nanotherapy: core–shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Qiangqiang Zhao ◽  
Duanfeng Jiang ◽  
Xiaoying Sun ◽  
Qiuyu Mo ◽  
Shaobin Chen ◽  
...  
Keyword(s):  
Mesoporous Silica Nanoparticles ◽  
Treatment Options ◽  
Inflammatory Factors ◽  
Main Method ◽  
Tnf Α ◽  
Good Biocompatibility ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
New Treatment ◽  
Lymphoma Therapy

Abstract Background Non-Hodgkin’s lymphoma (NHL) is a malignant disease of lymphoid tissue. At present, chemotherapy is still the main method for the treatment of NHL. R-CHOP can significantly improve the survival rate of patients. Unfortunately, DOX is the main cytotoxic drug in R-CHOP and it can lead to adverse reactions. Therefore, it is particularly important to uncover new treatment options for NHL. Results In this study, a novel anti-tumor nanoparticle complex Nm@MSNs-DOX/SM was designed and constructed in this study. Mesoporous silica nanoparticles (MSNs) loaded with Doxorubicin (DOX) and anti-inflammatory drugs Shanzhiside methylester (SM) were used as the core of nanoparticles. Neutrophil membrane (Nm) can be coated with multiple nanonuclei as a shell. DOX combined with SM can enhance the anti-tumor effect, and induce apoptosis of lymphoma cells and inhibit the expression of inflammatory factors related to tumorigenesis depending on the regulation of Bcl-2 family-mediated mitochondrial pathways, such as TNF-α and IL-1β. Consequently, the tumor microenvironment (TME) was reshaped, and the anti-tumor effect of DOX was amplified. Besides, Nm has good biocompatibility and can enhance the EPR effect of Nm@MSNs-DOX/SM and increase the effect of active targeting tumors. Conclusions This suggests that the Nm-modified drug delivery system Nm@MSNs-DOX/SM is a promising targeted chemotherapy and anti-inflammatory therapy nanocomplex, and may be employed as a specific and efficient anti-Lymphoma therapy.

scholarly journals Beyond the guidelines management of juvenile idiopathic arthritis: a case report of a girl with polyarticular disease refractory to multiple treatment options and Leri Weill syndrome

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Vana Vukić ◽  
Ana Smajo ◽  
Mandica Vidović ◽  
Rudolf Vukojević ◽  
Miroslav Harjaček ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Case Report ◽  
Treatment Options ◽  
Janus Kinase ◽  
Musculoskeletal Symptoms ◽  
Multiple Treatment ◽  
Number Of Patients ◽  
Systemic Glucocorticoids ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Abstract Background The last two decades brought new treatment options and high quality guidelines into the paediatric rheumatologic practice. Nevertheless, a number of patients still present a diagnostic and therapeutic challenge due to combination of vague symptoms and unresponsiveness to available treatment modalities. Case presentation We report a case of sixteen years old girl suffering from polyarticular type of juvenile idiopathic arthritis refractory to multiple treatment options. She first presented at the age of 4 with swelling and contractures of both knees. Her symptoms were initially unresponsive to nonsteroidal anti-inflammatory drugs and progressed despite treatment with intraarticular and systemic glucocorticoids and methotrexate. Throughout the years, she received several biologics together with continuous administration of nonsteroidal anti-inflammatory drugs and disease modifying anti-rheumatic drugs as well as intraarticular and systemic glucocorticoids in disease flares. However, none of this options  provided a permanent remission, so various other modalities, as well as other possible diagnoses were constantly being considered. Eventually she became dependent on a daily dose of systemic glucocorticoids. In 2018, the treatment with Janus kinase inhibitor tofacitinib was initiated, which led to gradual amelioration of musculoskeletal symptoms, improvement of inflammatory markers and overall well-being, as well as to the weaning of systemic glucocorticoids. As the swelling of the wrists subsided for the first time in many years, Madelung’s deformity was noticed, first clinically, and later radiographically as well. Genetic analysis revealed short-stature homeobox gene deficiency and confirmed the diagnosis of Leri Weill syndrome. Conclusions This case report emphasizes the need for reporting refractory, complicated cases from everyday clinical practice in order to build-up the overall knowledge and share experience which is complementary to available guidelines. Individual reports of difficult to treat cases, especially when additional diagnoses are involved, can be helpful for physicians treating patients with common rheumatological diseases such as juvenile idiopathic arthritis.

scholarly journals Macrophage Activation and Cytokine Release Syndrome in COVID-19: Current Updates and Analysis of Repurposed and Investigational Anti-Cytokine Drugs

Drug Research ◽  
2021 ◽  
Author(s):  
Ashif Iqubal ◽  
Farazul Hoda ◽  
Abul Kalam Najmi ◽  
Syed Ehtaishamul Haque
Keyword(s):  
Immune Response ◽  
Clinical Trials ◽  
Macrophage Activation ◽  
Fatality Rate ◽  
Cytokine Storm ◽  
Cytokine Release ◽  
Cytokine Release Syndrome ◽  
Disease Condition ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

AbstractCoronavirus disease (COVID-19) emerged from Wuhan, has now become pandemic and the mortality rate is growing exponentially. Clinical complication and fatality rate is much higher for patients having co-morbid issues. Compromised immune response and hyper inflammation is hall mark of pathogenesis and major cause of mortality. Cytokine release syndrome (CRS) or cytokine storm is a term used to affiliate the situation of hyper inflammation and therefore use of anti-cytokine and anti-inflammatory drugs is used to take care of this situation. Looking into the clinical benefit of these anti-inflammatory drugs, many of them enter into clinical trials. However, understanding the immunopathology of COVID-19 is important otherwise, indiscriminate use of these drugs could be fetal as there exists a very fine line of difference between viral clearing cytokines and inflammatory cytokines. If any drug suppresses the viral clearing cytokines, it will worsen the situation and hence, the use of these drugs must be based on the clinical condition, viral load, co-existing disease condition and severity of the infection.

Osteoarthritis in Older Adults: Nonsteroidal Anti-Inflammatory Drugs Versus Opioids

2019 ◽  
Vol 34 (10) ◽  
pp. 674-677
Author(s):  
Callan Banks ◽  
Krystal Hughes ◽  
Cassandra Simpkins ◽  
David P. Elliott
Keyword(s):  
Older Adults ◽  
Treatment Option ◽  
Treatment Options ◽  
Persistent Pain ◽  
Careful Monitoring ◽  
Patient Profile ◽  
Central Nervous System Depression ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Upper Gastrointestinal

Persistent pain in older adults as a result of osteoarthritis (OA) has various treatment options, and all of them have significant risks. An oral nonsteroidal anti-inflammatory drug (NSAID) or an opioid can be considered as a treatment option when persistent pain is not controlled by nonpharmacological interventions and regularly scheduled doses of acetaminophen. However, NSAIDs are nephrotoxic and may cause upper gastrointestinal bleeding. These risks can be mitigated through the initiation of a proton-pump inhibitor and careful monitoring of renal function and serum electrolytes. A low-dose opioid taken as needed can be considered as a treatment option if the pain is not controlled by NSAIDs as long as the risks associated with central nervous system depression and dose escalation as a result of tolerance are monitored closely. The complete patient profile must be taken into consideration when determining the best option.

scholarly journals Secukinumab therapy in reactive arthritis: Report of two cases

2021 ◽  
Author(s):  
Prasanta Padhan ◽  
Debashis Maikap
Keyword(s):  
Reactive Arthritis ◽  
Tumour Necrosis ◽  
Treatment Options ◽  
Lower Limbs ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Immune Mediated ◽  
Factor Inhibitor ◽  
Inflammatory Drugs ◽  
Necrosis Factor

ABSTRACT Reactive arthritis (ReA) is an immune-mediated aseptic synovitis resulting either from genitourinary or gastrointestinal tract, commonly presenting as oligoarthritis of the lower limbs and rarely urethritis and conjunctivitis. The treatment options include nonsteroidal anti-inflammatory drugs, conventional disease-modifying antirheumatic drugs, and biologics in severe cases. We report successful use of secukinumab in two cases of chronic severe ReA who initially failed to treatment with tumour necrosis factor inhibitor.

scholarly journals Medikamentozno zdravljenje endometrioze: pregled stanja in nove možnosti zdravljenja

2016 ◽  
Vol 85 (7-8) ◽  
Author(s):  
Maja Jakič ◽  
Andrej Vogler ◽  
Tea Lanišnik Rižner
Keyword(s):  
Surgical Treatment ◽  
Treatment Options ◽  
Uterine Cavity ◽  
Pharmacological Treatments ◽  
Gynecological Examination ◽  
Combination Studies ◽  
Hormonal System ◽  
Gynecological Disease ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Endometriosis is a gynecological disease that is defined as the presence of endometrium-like tissue outside the uterine cavity, and it is one of the main causes of female infertility. Although there is unfortunately no known ‘optimal’ treatment for endometriosis, there are three treatment options: medication, surgical treatment, and a combination of both. The gold standard for diagnosis of endometriosis is a diagnostic laparoscopy, which is also therapeutic. Indications for pharmacological treatment of endometriosis include empirical treatment for patients with pelvic pain who are normal on gynecological examination, or who have recurrent disease after surgical treatment or in combination with surgical treatment. In everyday practice, non-steroid anti-inflammatory drugs, oral contraceptives, and progestins per os are used as first-line pharmacological treatments of endometriosis. Gonadoliberin agonists can be used as second-line treatment, although their use is discouraged. These medications can be used alone or in combination. Studies over the last 10 years have shown that many other agents have potential for treatment of endometriosis. These can be broadly classified into several groups: anti-inflammatory agents, and agents that interfere with the hormonal system, or with other pathophysiological processes, such as a disturbed immune system, reduced apoptosis, enhanced angiogenesis, degradation of the extracellular matrix, increased oxidative stress, and epigenetic changes. However, their introduction into routine use requires more convincing clinical studies to confirm their effectiveness.

scholarly journals NAPROXEN INDUCED ERYTHEMA MULTIFORME-A RARE CASE REPORT

2017 ◽  
Vol 9 (3) ◽  
pp. 294 ◽  
Author(s):  
Sai Keerthana P. C. ◽  
Anila K. N. ◽  
Reshma Reji
Keyword(s):  
Erythema Multiforme ◽  
Lupus Erythematosus ◽  
Rare Case ◽  
Symptomatic Treatment ◽  
Girl Child ◽  
Rare Case Report ◽  
History Of ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Custodial Parents

Erythema multiforme (EM) is a hypersensitivity reaction characterized by varying degrees of blisters and ulcerations. We report a case of 4 y old girl child born for Non-custodial parents who has a history of seizures and a known case of carbamazepine-induced SLE (Systemic Lupus Erythematosus) when treated with anti-inflammatory drugs developed EM. The offending drug was identified and withdrawn. Steroid was given as a part of symptomatic treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed groups of drugs for a variety of indications. The patient gradually improved and got discharged.

A retrospective survey evaluating the prescribing tendencies of UK veterinary surgeons, relating to the use of anti-inflammatory drugs in canine angiostrongylosis

2021 ◽  
Vol 12 (4) ◽  
pp. 186-192
Author(s):  
Amy Loverance ◽  
Ian Wright ◽  
Mark Dunning ◽  
Hany Elsheikha
Keyword(s):  
Endemic Area ◽  
Retrospective Survey ◽  
Regional Comparison ◽  
Immune Mediated ◽  
Veterinary Surgeons ◽  
Referral Practices ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
South East England ◽  
Survey Responses

Background: In addition to anti-parasitic therapy, appropriate supportive care is vital for the successful treatment of canine angiostrongylosis. Aim: This study sought to determine the prevalence and reasons for the use of corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs), by veterinarians, as a supportive treatment for canine angiostrongylosis. Specifically, the study investigated the use of anti-inflammatory drugs in the management of inflammation, anaphylaxis and immune-mediated thrombocytopenia, which can develop in some dogs infected by Angiostrongylus vasorum. Methods: These aims were achieved by surveying UK veterinarians from a non-endemic area, Yorkshire, and an endemic area, South East England, for canine angiostrongylosis. Responses were received from independent, corporate-owned and referral practices. Results: Overall, more veterinarians would administer corticosteroids (80%) compared with NSAIDs (40%). Most respondents surveyed stated administration would be case dependent, including the severity of perceived inflammation. Four of six veterinarians who would never administer NSAIDs cited coagulopathies as the reason for their decision-making. While the regional comparison here revealed no significant differences, wider sampling may produce identifiable trends. Conclusion: The survey responses revealed a lack of understanding of if, when, and why, anti-inflammatories should be administered. Imperatively, further research is needed to address this lacuna.

Sign in / Sign up

Export Citation Format

Share Document